A recent consensus on managing peritoneal mesothelioma reaffirms critical treatment strategies.
- Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is the standard for completely resectable cases.
- Strong agreement on using cisplatin-doxorubicin for HIPEC in routine care and performing a total parietal peritonectomy for all patients.
- Neoadjuvant chemotherapy recommended for patients with sarcomatoid or biphasic subtypes and specific disease characteristics.
These guidelines enhance decision-making frameworks for improved patient outcomes in surgical practice.
Journal Article by Chatterjee A, Rajagopal AK (…) Bhatt A et 9 al. in Indian J Surg Oncol
© The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2025. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.